Request for Nominations for Voting Members on a Public Advisory Committee; Tobacco Products Scientific Advisory Committee, 54777-54778 [2011-22548]
Download as PDF
<![CDATA[
erowe on DSK5CLS3C1PROD with NOTICES
Federal Register / Vol. 76, No. 171 / Friday, September 2, 2011 / Notices
annual update to the standard Federal
rate for discharges occurring during a
rate year, beginning in FY 2014. One of
the quality measures LTCHs are
required to collect and submit data on
is the Percent of Residents with Pressure
Ulcers That Are New or Have Worsened.
Currently, there are no mandatory
standardized data sets being used in
LTCHs. Therefore, we have created a
new data set to be used in LTCHs,
which incorporates data items
contained in other, well known and
clinically established pressure ulcer
data sets, including but not limited to
the Minimum Data Set 3.0 (MDS 3.0)
and CARE data set (Continuity
Assessment Records & Evaluation).
Beginning on October 1, 2012, LTCHs
will begin to use a data collection
document entitled the ‘‘LTCH CARE
Data Set’’ as the vehicle by which to
collect the pressure ulcer data for the
LTCH quality reporting program. This
data set consists of the following
components: (1) Pressure ulcer
documentation; (2) selected covariates
related to pressure ulcers; (3) patient
demographic information; and; (4) a
provider attestation section. The use of
the LTCH CARE Data Set is necessary in
order to allow CMS to collect LTCH
quality measures data in compliance
with Section 3004 of the Affordable
Care Act. There are no other reasonable
alternatives available to CMS for the
collection and submission of pressure
ulcer data. Form Number: CMS–10409
(OCN: 0938–New); Frequency:
Occasionally; Affected Public: Private
Sector: Business or other for-profit and
not-for-profit institutions; Number of
Respondents: 3,531; Total Annual
Responses: 3,531; Total Annual Hours:
883. (For policy questions regarding this
collection contact Caroline Gallaher at
410–786–8705. For all other issues call
410–786–1326.)
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS’ Web Site
address at https://www.cms.hhs.gov/
PaperworkReductionActof1995, or
e-mail your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov, or call the
Reports Clearance Office on (410) 786–
1326.
In commenting on the proposed
information collections please reference
the document identifier or OMB control
number. To be assured consideration,
comments and recommendations must
be submitted in one of the following
ways by November 1, 2011:
1. Electronically. You may submit
your comments electronically to https://
VerDate Mar<15>2010
15:37 Sep 01, 2011
Jkt 223001
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) accepting comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number llllll, Room
C4–26–05, 7500 Security Boulevard,
Baltimore, Maryland 21244–1850.
54777
‘‘Will there be transcripts of the
meeting?’’ the address for the Division
of Freedom of Information is corrected
to read ‘‘Division of Freedom of
Information (ELEM–1029), Food and
Drug Administration, 12420 Parklawn
Dr., Element Bldg., Rockville, MD
20857.’’
Dated: August 29, 2011.
Nancy K. Stade,
Deputy Director for Policy, Center for Devices
and Radiological Health.
[FR Doc. 2011–22475 Filed 9–1–11; 8:45 am]
Dated: August 30, 2011.
Martique Jones,
Director, Regulations Development Group,
Division B, Office of Strategic Operations and
Regulatory Affairs.
BILLING CODE 4160–01–P
[FR Doc. 2011–22583 Filed 9–1–11; 8:45 am]
Food and Drug Administration
BILLING CODE 4120–01–P
[Docket No. FDA–2011–N–0002]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Request for Nominations for Voting
Members on a Public Advisory
Committee; Tobacco Products
Scientific Advisory Committee
[Docket No. FDA–2011–N–0556]
AGENCY:
Center for Devices and Radiological
Health 510(k) Clearance Process;
Recommendations Proposed in
Institute of Medicine Report: ‘‘Medical
Devices and the Public’s Health, The
FDA 510(k) Clearance Process at 35
Years’’; Public Meeting; Correction
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug
Administration (FDA) is correcting a
notice that appeared in the Federal
Register of Friday, August 12, 2011 (76
FR 50230). The document announced a
public workshop entitled
‘‘Recommendations Proposed in
Institute of Medicine Report: ‘Medical
Devices and the Public’s Health, The
FDA 510(k) Clearance Process at 35
Years.’ ’’ The document was published
with an outdated address in the section
entitled ‘‘Will there be transcripts of the
meeting?’’ This document corrects that
error.
FOR FURTHER INFORMATION CONTACT:
Joyce Strong, Office of Policy, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 3208,
Silver Spring, MD 20993–0002, 301–
796–9148.
SUPPLEMENTARY INFORMATION: In FR Doc.
2011–20575, appearing on page 50230
in the Federal Register of Friday,
August 12, 2011, the following
correction is made:
1. On page 50231, in the second
column, under the section entitled
SUMMARY:
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Food and Drug Administration,
HHS.
Notice.
The Food and Drug
Administration (FDA) is requesting
nominations for members to serve on
the Tobacco Products Scientific
Advisory Committee, Center for
Tobacco Products.
FDA has a special interest in ensuring
that women, minority groups, and
individuals with disabilities are
adequately represented on advisory
committees and, therefore, encourages
nominations of qualified candidates
from these groups.
DATES: Nominations received on or
before November 1, 2011 will be given
first consideration for membership on
the Tobacco Products Scientific
Advisory Committee. Nominations
received after November 1, 2011 will be
considered for nomination to the
committee if nominees are still needed.
ADDRESSES: All nominations for
membership should be sent
electronically to cv@oc.fda.gov, or by
mail to Advisory Committee Oversight
and Management Staff, 10903 New
Hampshire Ave., Bldg. 32, Rm. 5103,
Silver Spring, MD 20993–0002.
FOR FURTHER INFORMATION CONTACT:
Regarding all nomination questions
for membership, the primary contact is:
Caryn Cohen, Office of Science,
Center for Tobacco Products, Food and
Drug Administration, 9200 Corporate
Blvd., Rockville, MD 20850, 1–877–
287–1373 (choose Option 4), FAX: 240–
276–3761, TPSAC@fda.hhs.gov.
SUMMARY:
E:\FR\FM\02SEN1.SGM
02SEN1
54778
Federal Register / Vol. 76, No. 171 / Friday, September 2, 2011 / Notices
Information about becoming a
member on an FDA advisory committee
can also be obtained by visiting FDA’s
Web site by using the following link:
https://www.fda.gov/
AdvisoryCommittees/default.htm.
SUPPLEMENTARY INFORMATION: FDA is
requesting nomination for voting
members on the Tobacco Products
Scientific Advisory Committee.
I. General Description of the Committee
Duties
The Tobacco Products Scientific
Advisory Committee (the Committee)
advises the Commissioner of Food and
Drugs (the Commissioner) or designee in
discharging responsibilities as they
relate to the regulation of tobacco
products. The Committee reviews and
evaluates safety, dependence, and
health issues relating to tobacco
products and provides appropriate
advice, information and
recommendations to the Commissioner.
II. Criteria for Voting Members
Members and the Chair are selected
by the Commissioner or designee from
among individuals knowledgeable in
the fields of medicine, medical ethics,
science, or technology involving the
manufacture, evaluation, or use of
tobacco products. Members will be
invited to serve for terms of up to 4
years. The Committee shall include nine
technically qualified voting members,
selected by the Commissioner or
designee. The nine voting members
shall be physicians, dentists, scientists,
or health care professionals practicing
in the area of oncology, pulmonology,
cardiology, toxicology, pharmacology,
addiction, or any other relevant
specialty.
erowe on DSK5CLS3C1PROD with NOTICES
III. Nomination Procedures
Any interested person may nominate
one or more qualified individuals for
membership on the advisory committee.
Self-nominations are also accepted.
Nominations must include a current,
complete resume or curriculum vitae for
each nominee, including current
business address and/or home address,
telephone number, and e-mail address if
available. Nominations must also
specify the advisory committee for
which the nominee recommended.
Nomination must also acknowledge that
the nominee is aware of the nomination
unless self-nominated. FDA will ask
potential candidates to provide detailed
information concerning such matters
related to financial holdings,
employment, and research grants and/or
contracts to permit evaluation of
possible sources of conflicts of interest.
VerDate Mar<15>2010
15:37 Sep 01, 2011
Jkt 223001
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: August 30, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2011–22548 Filed 9–1–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Literature Selection Technical Review
Committee.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended because the premature
disclosure of journals as potential titles
to be indexed by the National Library of
Medicine and the discussions would
likely to significantly frustrate
implementation of recommendations.
Name of Committee: Literature Selection
Technical Review Committee.
Date: October 27–28, 2011.
Open: October 27, 2011, 9 a.m. to 11 a.m.
Agenda: Administrative.
Place: National Library of Medicine,
Building 38, 2nd Floor, Board Room, 8600
Rockville Pike, Bethesda, MD 20894.
Closed: October 27, 2011, 11 a.m. to 5 p.m.
Agenda: To review and evaluate journals
as potential titles to be indexed by the
National Library of Medicine.
Place: National Library of Medicine,
Building 38, 2nd Floor, Board Room, 8600
Rockville Pike, Bethesda, MD 20894.
Closed: October 28, 2011, 8:30 a.m. to 2
p.m.
Agenda: To review and evaluate journals
as potential titles to be indexed by the
National Library of Medicine.
Place: National Library of Medicine,
Building 38, 2nd Floor, Board Room, 8600
Rockville Pike, Bethesda, MD 20894.
Contact Person: Sheldon Kotzin, MLS,
Associate Director, Division of Library
Operations, National Library of Medicine,
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
8600 Rockville Pike, Building 38, Room
2W06, Bethesda, MD 20892, 301–496–6921,
kotzins@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance
Program No. 93.879, Medical Library
Assistance, National Institutes of Health,
HHS).
Dated: August 29, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–22601 Filed 9–1–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Musculoskeletal, Oral
and Skin Sciences Integrated Review Group,
Musculoskeletal Tissue Engineering Study
Section.
Date: September 29–30, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Jean D. Sipe, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4106,
E:\FR\FM\02SEN1.SGM
02SEN1
]]>Agencies
[Federal Register Volume 76, Number 171 (Friday, September 2, 2011)]
[Notices]
[Pages 54777-54778]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-22548]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0002]
Request for Nominations for Voting Members on a Public Advisory
Committee; Tobacco Products Scientific Advisory Committee
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is requesting
nominations for members to serve on the Tobacco Products Scientific
Advisory Committee, Center for Tobacco Products.
FDA has a special interest in ensuring that women, minority groups,
and individuals with disabilities are adequately represented on
advisory committees and, therefore, encourages nominations of qualified
candidates from these groups.
DATES: Nominations received on or before November 1, 2011 will be given
first consideration for membership on the Tobacco Products Scientific
Advisory Committee. Nominations received after November 1, 2011 will be
considered for nomination to the committee if nominees are still
needed.
ADDRESSES: All nominations for membership should be sent electronically
to cv@oc.fda.gov, or by mail to Advisory Committee Oversight and
Management Staff, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103, Silver
Spring, MD 20993-0002.
FOR FURTHER INFORMATION CONTACT:
Regarding all nomination questions for membership, the primary
contact is:
Caryn Cohen, Office of Science, Center for Tobacco Products, Food
and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 1-
877-287-1373 (choose Option 4), FAX: 240-276-3761, TPSAC@fda.hhs.gov.
[[Page 54778]]
Information about becoming a member on an FDA advisory committee
can also be obtained by visiting FDA's Web site by using the following
link: https://www.fda.gov/AdvisoryCommittees/default.htm.
SUPPLEMENTARY INFORMATION: FDA is requesting nomination for voting
members on the Tobacco Products Scientific Advisory Committee.
I. General Description of the Committee Duties
The Tobacco Products Scientific Advisory Committee (the Committee)
advises the Commissioner of Food and Drugs (the Commissioner) or
designee in discharging responsibilities as they relate to the
regulation of tobacco products. The Committee reviews and evaluates
safety, dependence, and health issues relating to tobacco products and
provides appropriate advice, information and recommendations to the
Commissioner.
II. Criteria for Voting Members
Members and the Chair are selected by the Commissioner or designee
from among individuals knowledgeable in the fields of medicine, medical
ethics, science, or technology involving the manufacture, evaluation,
or use of tobacco products. Members will be invited to serve for terms
of up to 4 years. The Committee shall include nine technically
qualified voting members, selected by the Commissioner or designee. The
nine voting members shall be physicians, dentists, scientists, or
health care professionals practicing in the area of oncology,
pulmonology, cardiology, toxicology, pharmacology, addiction, or any
other relevant specialty.
III. Nomination Procedures
Any interested person may nominate one or more qualified
individuals for membership on the advisory committee. Self-nominations
are also accepted. Nominations must include a current, complete resume
or curriculum vitae for each nominee, including current business
address and/or home address, telephone number, and e-mail address if
available. Nominations must also specify the advisory committee for
which the nominee recommended. Nomination must also acknowledge that
the nominee is aware of the nomination unless self-nominated. FDA will
ask potential candidates to provide detailed information concerning
such matters related to financial holdings, employment, and research
grants and/or contracts to permit evaluation of possible sources of
conflicts of interest.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.
Dated: August 30, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2011-22548 Filed 9-1-11; 8:45 am]
BILLING CODE 4160-01-P
